A Dual Stimuli‐Responsive Nanoplatform Loaded Pt IV ‐Triptolide Prodrug for Achieving Synergistic Therapy toward Breast Cancer
Advanced Healthcare Materials · 2023-11 · 12 (28)
DOI: 10.1002/adhm.202301328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 09.07.2023. Verfasst von Kang Fang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Chemical Assessment and Sustainability, School of Chemical Science and Engineering. Department of Oncology, East Hospital …. Hauptthemen laut MEDLINE: Breast Neoplasms, Prodrugs, Diterpenes. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
To strengthen the antitumor efficacy and avoid toxicity to normal cells of cisplatin and triptolide, herein, an acid and glutathione (GSH) dual‐controlled nanoplatform for enhanced cancer treatment through the synergy of both “1+1” apoptosis and “1+1” ferroptosis is designed. Remarkably, ZIF8 in response to tumor microenvironment enhances drug targeting and protects drugs from premature degradation. Meanwhile, the Pt IV center can be easily reduced to cisplatin because of the large amount of GSH, thus liberating the triptolide as the coordinated ligand. The released cisplatin and hemin in turn boost the tumor cell “1+1” apoptosis through chemotherapy and photodynamic therapy, respectively. Furthermore, GSH reduction through Pt IV weakens the activation of glutathione peroxidase 4 (GPX4) effectively. The released triptolide can inhibit the expressions of GSH by regulating nuclear factor E2 related factor 2 (Nrf2), further promoting membrane lipid peroxidation, thus “1+1” ferroptosis can be achieved. Both in vitro and in vivo results demonstrate that the nanosystem can not only perform superior specificity and therapeutic outcomes but also reduce the toxicity to normal cells/tissues of cisplatin and triptolide effectively. Overall, the prodrug‐based smart system provides an efficient therapeutic strategy for cancer treatment by virtue of the effect of enhanced “1+1” apoptosis and “1+1” ferroptosis therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Key Laboratory of Chemical Assessment and Sustainability, School of Chemical Science and Engineering. Department of Oncology, East Hospital Affiliated to Tongji University, School of Medicine, Tongji University…
- School of Medicine, Shanghai University, Shanghai, 200444, China.
ORCID-Profile: Shuo Shi
Förderung
- Natural Science Foundation of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Fang, K., Sun, Y., Yang, J., Hu, X., Chen, M., Li, R., Yang, X., Fan, T., Wu, J., Tong, X., Dong, C., & Shi, S. (2023). A Dual Stimuli‐Responsive Nanoplatform Loaded Pt IV ‐Triptolide Prodrug for Achieving Synergistic Therapy toward Breast Cancer. Advanced Healthcare Materials, 12(28). https://doi.org/10.1002/adhm.202301328
Vancouver
Fang K, Sun Y, Yang J, Hu X, Chen M, Li R, et al. A Dual Stimuli‐Responsive Nanoplatform Loaded Pt IV ‐Triptolide Prodrug for Achieving Synergistic Therapy toward Breast Cancer. Advanced Healthcare Materials. 2023;12(28). doi:10.1002/adhm.202301328
BibTeX
@article{Fang2023,
author = {Fang, Kang and Sun, Yanting and Yang, Jingxian and Hu, Xiaochun and Chen, Mengyao and Li, Ruihao and Yang, Xinda and Fan, Ting and Wu, Junjie and Tong, Xiaohan and Dong, Chunyan and Shi, Shuo},
title = {A Dual Stimuli‐Responsive Nanoplatform Loaded Pt IV ‐Triptolide Prodrug for Achieving Synergistic Therapy toward Breast Cancer},
journal = {Advanced Healthcare Materials},
year = {2023},
volume = {12},
number = {28},
doi = {10.1002/adhm.202301328}
}
EUVIMED